Direct oral anticoagulants in cancer-associated venous thromboembolism

Direct oral anticoagulants in cancer-associated venous thromboembolism

This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and treatment of venous thromboembolism (VTE) in cancer patients. In accordance with actual guidelines, the duration of anticoagulant therapy for cancer-associated venous thrombosis should be at least 6 months....

Full description

Bibliographic Details
Main Authors: Kirill Lobastov, Ilya Schastlivtsev, Irina Kanzafarova
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Vascular Investigation and Therapy
Subjects:
direct oral anticoagulants
malignancy
pulmonary embolism
venous thromboembolism
venous thrombosis
Online Access:http://www.vitonline.org/article.asp?issn=2589-9686;year=2020;volume=3;issue=2;spage=46;epage=53;aulast=Lobastov

Internet

http://www.vitonline.org/article.asp?issn=2589-9686;year=2020;volume=3;issue=2;spage=46;epage=53;aulast=Lobastov

Similar Items